That the EU AI Act is a private equity issue isn't a seller's hypothesis: a leading audit firm dedicated a study to it, Impact of the EU AI Act in private equity (2024). The underlying message is simple — for a fund, AI regulatory risk isn't managed deal by deal. It's managed at the portfolio level.
A mid-market fund with ten AI holdings carries ten distinct AI Act exposures: ten possible Annex III classifications, ten levels of compliance with Articles 9-15, ten latent Article 99 fines. None appears on the balance sheet. All wake up at the most expensive moment: a sale, a follow-on round, an enforcement action. The risk is diffuse, therefore invisible — until it's expensive.
It's also a fiduciary-duty matter. An Operating Partner who doesn't know which asset in the portfolio is high-risk under the AI Act can't answer the question that the investment committee — and the LPs — will eventually ask.
Scoring each holding once isn't enough: the law evolves (the Digital Omnibus showed that), and so do the products. That's the logic of MB Shield™ — Portfolio: a D7™ score per asset, a quarterly dashboard, targeted alerts and re-attestation. The fund moves from diffuse, unpriced exposure to a monitored, dated and board-presentable risk — before the sale, not during.